Stratec SE (SBS) Fair Value & Analysis
Healthcare · DE · Market cap €215M
Fair value as of: Jun 24, 2026
From 9 valuation models · updated 5 days ago
Share price −1.7% over the past month.
Price vs Fair Value (12 months)
12‑month range €16.50 – €31.96 · fair‑value band €14.51 – €30.17 · the €17.36 price screens below the €22.34 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Stratec SE (SBS) currently trades at €17.36, while our model-based Fair Value estimate is €22.34 — implying the stock looks roughly 28.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Stratec SE generated revenue of €251M at a net margin of -0.1%. Revenue declined 11.1% year over year. It earns a return on equity of -0.1%. Net debt stands at €109M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Stratec SE reported revenue of €251M in FY2025 versus €287M in FY2021, a compound −3.3%/yr. Reported net income was −€242K in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Stratec SE (SBS) undervalued?
What is the fair value of SBS?
What is the quality score of SBS?
What is the revenue of Stratec SE (SBS)?
What is the net profit margin of SBS?
Does Stratec SE pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.